CTL-Dependent and -Independent Antitumor Immunity Is Determined by the Tumor Not the Vaccine

Journal of Immunology

Volumn 172, Issue 9, 2004, Pages 5200-5205

  Leitch, Jaina ^a   Fraser, Katie ^a   Lane, Cecilia ^a   Putzu, Kelley ^a   Adema, Gosse J ^b   Zhang, Qian Jin ^c   Jefferies, Wilfred A ^c   Bramson, Jonathan L ^a   Wan, Yonghong ^a,d  

^a MCMASTER UNIVERSITY   (Canada)

^b RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

^c UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^d MCMASTER UNIVERSITY   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOVIRUS VECTOR; CD8 ANTIGEN; COMPLEMENTARY DNA; GLYCOPROTEIN GP 100; TUMOR VACCINE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER; CANCER PREVENTION; CELL STRAIN; CELL STRAIN B16F10; CELLULAR IMMUNITY; CONTROLLED STUDY; CROSS REACTION; CYTOLYSIS; CYTOTOXIC T LYMPHOCYTE; DENDRITIC CELL; DRUG EFFECT; DRUG MECHANISM; DRUG SCREENING; MOUSE; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL; PROTEIN EXPRESSION; TUMOR IMMUNITY;

EID: 2142644402     PISSN: 00221767     EISSN: None     Source Type: Journal    
DOI: 10.4049/jimmunol.172.9.5200     Document Type: Article

References (27)

1. Bramson, J. L., and Y. H. Wan. 2002. The efficacy of genetic vaccination is dependent upon the nature of the vector system and antigen. Expert Opin. Biol. Ther. 2:75.
2. Zhou, Y., M. L. Bosch, and M. L. Salgaller. 2002. Current methods for loading dendritic cells with tumor antigen for the induction of antitumor immunity. J. Immunother. 25:289.
3. Wan, Y., J. L. Bramson, R. Carter, F. Graham, and J. Gauldie. 1997. Dendritic cells transduced with an adenoviral vector encoding a model tumor-associated antigen for tumor vaccination. Hum. Gene Ther. 8:1355.
4. Wan, Y., J. L. Bramson, A. Pilon, Q. Zhu, and J. Gauldie. 2000. Genetically modified dendritic cells prime autoreactive T cells through a pathway independent of CD40L and interleukin 12: implications for cancer vaccines. Cancer Res. 60:3247.
5. + T cell-dependent mechanism. Gene Ther. 8:1255.
6. Schreurs, M. W., A. J. de Boer, C. G. Figdor, and G. J. Adema. 1998. Genetic vaccination against the melanocyte lineage-specific antigen gp100 induces cytotoxic T lymphocyte-mediated tumor protection. Cancer Res. 58:2509.
7. Overwijk, W. W., A. Tsung, K. R. Irvine, M. R. Parkhurst, T. J. Goletz, K. Tsung, M. W. Carroll, C. Liu, B. Moss, S. A. Rosenberg, and N. P. Restifo. 1998. gp100/pMel 17 is a murine tumor rejection antigen: induction of "self"-reactive. tumoricidal T cells using high-affinity, altered peptide ligand. J. Exp. Med. 188:277.
8. Hitt, M., Bett, A. J., Prevec, L., and Graham, F. L. 1998. Construction and propagation of human adenovirus vectors. In Cell Biology: A Laboratory Handbook, J. E. Celis, ed. Academic Press, San Diego, p. 500.
9. Alimonti, J., Q.-J. Zhang, R. Gabathuler, G. Reid, S. S. Chen, and W. A. Jefferies. 2000. TAP expression provides a general method for improving the recognition of malignant cells in vivo. Nat. Biotechnol. 18:515.
10. Seliger, B., U. Wollscheid, F. Momburg, T. Blankenstein, and C. Huber. 2001. Characterization of the major histocompatibility complex class I deficiencies in B16 melanoma cells. Cancer Res. 61:1095.
11. Wan, Y., P. Emtage, Q. Zhu, R. Foley, A. Pilon, B. Roberts, and J. Gauldie. 1999. Enhanced immune response to the melanoma antigen gp100 using recombinant adenovirus-transduced dendritic cells. Cell. Immunol. 198:131.
12. Shibagaki, N., and M. C. Udey. 2002. Dendritic cells transduced with protein antigens induce cytotoxic lymphocytes and elicit antitumor immunity. J. Immunol. 168:2393.
13. Celluzzi, C. M., and L. D. Falo, Jr. 1997. Epidermal dendritic cells induce potent antigen-specific CTL-mediated immunity. J. Invest. Dermatol. 108:716.
14. Brossart, P., A. W. Goldrath, E. A. Butz, S. Martin, and M. J. Bevan. 1997. Virus-mediated delivery of antigenic epitopes into dendritic cells as a means to induce CTL. J. Immunol. 158:3270.
15. + tumors. Cancer Res. 58:4902.
16. + T cells from melanoma patients reveals inefficient antigen processing. Eur. J. Immunol. 31:2642.
17. Valmori, D., U. Gileadi, C. Servis, P. R. Dunbar, J. C. Cerottini, P. Romero, V. Cerundolo, and F. Levy. 1999. Modulation of proteasomal activity required for the generation of a cytotoxic T lymphocyte-defined peptide derived from the tumor antigen MAGE-3. J. Exp. Med. 189:895.
18. Morel, S., F. Levy, O. Burlet-Schiltz, F. Brasseur, M. Probst-Kepper, A. L. Peitrequin, B. Monsarrat, R. Van Velthoven, J. C. Cerottini, T. Boon, et al. 2000. Processing of some antigens by the standard proteasome but not by the immunoproteasome results in poor presentation by dendritic cells. Immunity 12:107.
19. Uebel, S., and R. Tampe. 1999. Specificity of the proteasome and the TAP transporter. Curr. Opin. Immunol. 11:203.
20. Gouttefangeas, C., and H. G. Rammensee. 2000. Problem solving for tumor immunotherapy. Nat. Biotechnol. 18:491.
21. + effector T cells mediate indirect interleukin-12- and interferon-γ-dependent suppression of autologous HLA-negative lung tumor xenografts in severe combined immunodeficient mice. Cancer Res. 62:2611.
22. + T cell-mediated tumor rejection involves inhibition of angiogenesis that is dependent on IFNγ receptor expression by nonhematopoietic cells. Immunity 12:677.
23. + T cells eliminate MHC class II-negative cancer cells in vivo by indirect effects of IFN-γ. Proc. Natl. Acad. Sci. USA 96:8633.
24. + T cells in the antitumor immune response. J. Exp. Med. 188:2357.
25. Steinman, R. M., and M. Pope. 2002. Exploiting dendritic cells to improve vaccine efficacy. J. Clin. Invest. 109:1519.
26. Toes, R. E., F. Ossendorp, R. Offringa, and C. J. Melief. 1999. CD4 T cells and their role in antitumor immune responses. J. Exp. Med. 189:753.
27. + T cell responses in antitumor immunity. Curr. Opin. Immunol. 10:588.